# Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix

> **NCT03193645** · — · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 150 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT03193645
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-27
- **Primary completion:** 2018-06-30
- **Final completion:** 2019-01-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193645, "Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03193645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*